The autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine)

N/A

Report date: 2024/03/01 20:05:21

Base Information

Drug NameThe autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine)
Drug Alias NameFKC288FKC-288
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein modulatorsB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-cell maturation proteinB-lymphocyte antigen CD19
Therapy Area/IndicationsImmunoglobulin G4-Related DiseaseAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisLupus Nephritis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesNanjing University School Of Medicine
Inactive CompaniesN/A
Active IndicationsImmunoglobulin G4-Related DiseaseAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisLupus Nephritis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A